StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. Since March 2024, a Phase II physician-led clinical trial has been initiated with Osaka University Graduate School of Medicine.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRim","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4599-20260713-01.pdf","jir_short_summary":"StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. Since March 2024, a Phase II physician-led clinical trial has been initiated with Osaka University Graduate School of Medicine.","jir_summary":"### Progress in Patent Registration and Pharmaceutical Development\nStemRim has registered a patent in Canada for a new therapeutic drug using Ledasemide targeting cardiomyopathy, old myocardial infarction, and chronic heart failure caused by these conditions. This ensures expansion of application scope within North America and the potential for drug development. Currently, a Phase II physician-led clinical trial is underway at Osaka University Hospital targeting ischemic cardiomyopathy, with high expectations for future clinical development.\n\n### Future Outlook and Impact on Performance\nThis patent registration indicates progress in the research and development of the drug and application expansion, representing a significant step toward future clinical trials and commercialization. While no direct impact on the full-year earnings for July 2026 is anticipated, advancements in drug development may lead to future business expansion and revenue generation.","jir_financial_highlights":"Patent Registration Region: Canada (New registration)\nApplication Number: 3,051,825 (New)\nExpansion of Treatment Application Range: Cardiomyopathy, Old Myocardial Infarction, Chronic Heart Failure (Expansion)","jir_category":"","jir_hashtags":"#StemRim, #PatentRegistration, #Cardiomyopathy, #PharmaceuticalDevelopment, #JapanStocks","jir_key_figures":"Patent Registration Number: 3,051,825\nTreatment Application Range: Cardiomyopathy, Old Myocardial Infarction, Chronic Heart Failure\nPhase II physician-led clinical trial start: March 2024","jir_meta_title":"\u3010StemRim\u3011Canada Patent Registration for Heart Failure Treatment\uff5cJuly 2026","jir_meta_description":"StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. A Phase II clinical trial is also underway, with expectations for future development.","jir_og_title":"\u3010StemRim\u3011Canada Patent Registration for Heart Failure Treatment\uff5cJuly 2026","jir_og_description":"StemRim announced the patent registration and initiation of clinical trials for Ledasemide. Expectations for future pharmaceutical development are high.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-79918","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n